Search results
Results from the WOW.Com Content Network
One cycle of ABVD chemotherapy is typically given over 4 weeks in two doses, with the first on day 1 and the second dose on day 15. All four of the chemotherapy drugs are given intravenously. ABVD chemotherapy is usually given in the outpatient setting — that is, it does not require hospitalization. [citation needed]
Hepatic arterial infusion (HAI) is a medical procedure that delivers chemotherapy directly to the liver. The procedure, mostly used in combination with systemic chemotherapy, plays a role in the treatment of liver metastases in patients with colorectal cancer (CRC). [ 1 ]
Metronomic chemotherapy, which involves regularly giving patients low dosages of chemotherapy drugs, is one instance of this. [46] This technique has been shown to have the potential to change the tumor microenvironment and limit tumor growth. [47] It is yet unknown how best to employ metronomic chemotherapy, especially for varied cancer types ...
Trastuzumab, a monoclonal antibody against HER2, added to chemotherapy, has been proven in clinical trials to extend the time to disease progression, increase response rates, prolong response duration, reduce the death rate at 1 year, improve overall survival, and lower the risk of death by 20%. This demonstrates trastuzumab's significant ...
Chemotherapy may be given with a curative intent (which almost always involves combinations of drugs), or it may aim only to prolong life or to reduce symptoms (palliative chemotherapy). Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology. [1] [2]
Feelings of nausea occur among approximately 7 out of every 10 people (70%) but this can be well controlled with anti-nausea drugs. There are many options available to treat chemotherapy-induced nausea and vomiting. Pain in the vein during the infusion of oxaliplatin or folinic acid – This can be managed by decreasing the rate of infusion.
Incomplete response or stable disease (SD): Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits; Progressive disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions; Evaluation of best overall response
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.